Literature DB >> 27365490

Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.

Maja Hinge1, Kristian T Andersen2, Thomas Lund3, Henrik B Jørgensen4, Paw C Holdgaard4, Tina E Ormstrup5, Lone L Østergaard5, Torben Plesner2.   

Abstract

Entities:  

Keywords:  bone disease; bone marker; bone sclerosis; multiple myeloma; osteolytic lesion

Mesh：

Year:  2016        PMID： 27365490      PMCID： PMC5046665          DOI： 10.3324/haematol.2016.144477

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

2.  Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.

Authors:  Dianne Pulte; Lina Jansen; Felipe A Castro; Katharina Emrich; Alexander Katalinic; Bernd Holleczek; Hermann Brenner
Journal:  Br J Haematol       Date:  2015-06-30       Impact factor: 6.998

3.  A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.

Authors:  Maurizio Zangari; Shmuel Yaccoby; Lisa Pappas; Federica Cavallo; Naveen Sanath Kumar; Subramanian Ranganathan; Larry J Suva; J Michael Gruenwald; Steven Kern; Fenghuang Zhan; Dixie Esseltine; Guido Tricot
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

4.  First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

Authors:  Thomas Lund; Kent Søe; Niels Abildgaard; Patrick Garnero; Per T Pedersen; Tina Ormstrup; Jean-Marie Delaissé; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-07-22       Impact factor: 2.997

5.  First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.

Authors:  Patrizia Tosi; Elena Zamagni; Claudia Cellini; Raffaele Parente; Delia Cangini; Paola Tacchetti; Giulia Perrone; Michela Ceccolini; Paola Boni; Sante Tura; Michele Baccarani; Michele Cavo
Journal:  Eur J Haematol       Date:  2006-02-15       Impact factor: 2.997

6.  The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.

Authors:  Evangelos Terpos; Dimitrios Christoulas; Efstathios Kastritis; Eirini Katodritou; Athanasios Papatheodorou; Anastasia Pouli; Marie-Christine Kyrtsonis; Eurydiki Michalis; Xenophon Papanikolaou; Maria Gkotzamanidou; Efstathios Koulieris; Maria Gavriatopoulou; Konstantinos Zervas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2014-01       Impact factor: 10.047

7.  Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.

Authors:  Thomas L Andersen; Kent Søe; Teis E Sondergaard; Torben Plesner; Jean-Marie Delaisse
Journal:  Br J Haematol       Date:  2009-11-16       Impact factor: 6.998

8.  Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.

Authors:  Maximilian Schulze; Katja Weisel; Caroline Grandjean; Katharina Oehrlein; Manola Zago; Daniel Spira; Marius Horger
Journal:  AJR Am J Roentgenol       Date:  2014-01       Impact factor: 3.959

Review 9.  The effects of bortezomib on bone disease in patients with multiple myeloma.

Authors:  Mohamad Mohty; Florent Malard; Bilal Mohty; Bipin Savani; Philippe Moreau; Evangelos Terpos
Journal:  Cancer       Date:  2013-11-18       Impact factor: 6.860

Review 10.  The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation.

Authors:  Jean-Marie Delaisse
Journal:  Bonekey Rep       Date:  2014-08-06
View more
  5 in total

1.  Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Authors:  Meera Mohan; Rohan S Samant; Donghoon Yoon; Amy F Buros; Antonio Branca; Corey O Montgomery; Richard Nicholas; Larry J Suva; Roy Morello; Sharmilan Thanendrarajan; Carolina Schinke; Shmuel Yaccoby; Frits van Rhee; Faith E Davies; Gareth J Morgan; Maurizio Zangari
Journal:  J Bone Miner Res       Date:  2017-03-27       Impact factor: 6.741

2.  Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.

Authors:  Meera Mohan; Manoj Kumar; Rohan Samant; Rudy Van Hemert; Erming Tian; Shivang Desai; Frits van Rhee; Sharmilan Thanendrarajan; Carolina Schinke; Larry J Suva; Shobhit Sharma; Mohamed Milad; Samantha Kendrick; Maurizio Zangari
Journal:  Bone       Date:  2021-02-06       Impact factor: 4.398

3.  Can a Novel Scoring System Improve on the Mirels Score in Predicting the Fracture Risk in Patients with Multiple Myeloma?

Authors:  Gregory R Toci; Jarred A Bressner; Carol D Morris; Laura Fayad; Adam S Levin
Journal:  Clin Orthop Relat Res       Date:  2021-03-01       Impact factor: 4.755

Review 4.  Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.

Authors:  Sonia Vallet; Julia-Marie Filzmoser; Martin Pecherstorfer; Klaus Podar
Journal:  Pharmaceutics       Date:  2018-10-24       Impact factor: 6.321

Review 5.  Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.

Authors:  Chia-Hung Yen; Chin-Mu Hsu; Samuel Yien Hsiao; Hui-Hua Hsiao
Journal:  Int J Mol Sci       Date:  2020-09-14       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.